U.S., Oct. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07868835) titled 'Oral VK2735 for Weight Management Phase 3 (SUNRISE 1)' on Oct. 05.
Brief Summary: This study is one of two planned Phase 3 studies to support the weight management indication for VK2735 Oral in obese (BMI >= 30 kg/m2) or overweight (BMI >= 27kg/m2) adults with at least one weight-related comorbidity without type 2 diabetes mellitus.
Study Start Date: Oct. 15
Study Type: INTERVENTIONAL
Condition:
Weight Loss
Intervention:
DRUG: VK2735
VK2735 Oral is a peptide GLP-1 and GIP dual agonist administered once daily
DRUG: Placebo comparator
Placebo comparator administered orally once daily
Recruitment Status: NOT_YET_RECRUITING
S...